Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.

Duinkerken S, Horrevorts SK, Kalay H, Ambrosini M, Rutte L, de Gruijl TD, Garcia-Vallejo JJ, van Kooyk Y.

Theranostics. 2019 Aug 12;9(20):5797-5809. doi: 10.7150/thno.35059. eCollection 2019.

2.

Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination.

Horrevorts SK, Stolk DA, Ven RV, Hulst M, Hof BVH, Duinkerken S, Heineke MH, Ma W, Dusoswa SA, Nieuwland R, Garcia-Vallejo JJ, Loosdrecht AAV, de Gruijl TD, Vliet SJV, van Kooyk Y.

Cancers (Basel). 2019 Aug 28;11(9). pii: E1266. doi: 10.3390/cancers11091266.

3.

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, Rodrigues GB, Lock M, Yaremko BP, Bauman GS, Ahmad B, Schellenberg D, Liu M, Gaede S, Laba J, Mulroy L, Senthi S, Louie AV, Swaminath A, Chalmers A, Warner A, Slotman BJ, de Gruijl TD, Allan A, Senan S.

BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.

4.

Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation.

van Leeuwen-Kerkhoff N, Westers TM, Poddighe PJ, de Gruijl TD, Kordasti S, van de Loosdrecht AA.

Haematologica. 2019 Jul 4. pii: haematol.2019.219303. doi: 10.3324/haematol.2019.219303. [Epub ahead of print]

5.

Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node.

van Pul KM, Vuylsteke RJCLM, van de Ven R, Te Velde EA, Rutgers EJT, van den Tol PM, Stockmann HBAC, de Gruijl TD.

J Immunother Cancer. 2019 May 22;7(1):133. doi: 10.1186/s40425-019-0605-1.

6.

Unlocking the therapeutic potential of primary tumor-draining lymph nodes.

Rotman J, Koster BD, Jordanova ES, Heeren AM, de Gruijl TD.

Cancer Immunol Immunother. 2019 Apr 3. doi: 10.1007/s00262-019-02330-y. [Epub ahead of print] Review.

PMID:
30944963
7.

Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM.

Cancer Immunol Immunother. 2019 Jun;68(6):1037. doi: 10.1007/s00262-019-02328-6.

PMID:
30919028
8.

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM.

Cancer Immunol Immunother. 2019 Jun;68(6):1025-1035. doi: 10.1007/s00262-019-02320-0. Epub 2019 Mar 9. Erratum in: Cancer Immunol Immunother. 2019 Mar 27;:.

9.

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Werter IM, Huijts CM, Lougheed SM, Hamberg P, Polee MB, Tascilar M, Los M, Haanen JBAG, Helgason HH, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 May;68(5):787-798. doi: 10.1007/s00262-019-02313-z. Epub 2019 Feb 11.

PMID:
30756132
10.

Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.

Heeren AM, Rotman J, Stam AGM, Pocorni N, Gassama AA, Samuels S, Bleeker MCG, Mom CH, Zijlmans HJMAA, Kenter GG, Jordanova ES, de Gruijl TD.

J Immunother Cancer. 2019 Feb 12;7(1):43. doi: 10.1186/s40425-019-0526-z.

11.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Mar;68(3):503-515. doi: 10.1007/s00262-018-2288-8. Epub 2019 Jan 17.

12.

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

King LA, Lameris R, de Gruijl TD, van der Vliet HJ.

Front Immunol. 2018 Nov 20;9:2606. doi: 10.3389/fimmu.2018.02606. eCollection 2018.

13.

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Feb;68(2):319-329. doi: 10.1007/s00262-018-2248-3. Epub 2018 Nov 9.

14.

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ.

Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.

15.

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.

Stolk D, van der Vliet HJ, de Gruijl TD, van Kooyk Y, Exley MA.

Front Immunol. 2018 Sep 21;9:1990. doi: 10.3389/fimmu.2018.01990. eCollection 2018. Review.

16.

Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.

Baird JR, Bell RB, Troesch V, Friedman D, Bambina S, Kramer G, Blair TC, Medler T, Wu Y, Sun Z, de Gruijl TD, van de Ven R, Leidner RS, Crittenden MR, Gough MJ.

Cancer Res. 2018 Nov 1;78(21):6308-6319. doi: 10.1158/0008-5472.CAN-18-1652. Epub 2018 Sep 17.

PMID:
30224374
17.

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP.

Blood. 2018 Nov 22;132(21):2260-2272. doi: 10.1182/blood-2017-12-822569. Epub 2018 Sep 13.

PMID:
30213872
18.
19.

Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, Kordasti S, Bontkes HJ, Lindstedt M, de Gruijl TD, van de Loosdrecht AA.

Front Immunol. 2018 Jul 16;9:1619. doi: 10.3389/fimmu.2018.01619. eCollection 2018.

20.

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Heeren AM, van Dijk I, Berry DRAI, Khelil M, Ferns D, Kole J, Musters RJP, Thijssen VL, Mom CH, Kenter GG, Bleeker MCG, de Gruijl TD, Jordanova ES.

Front Immunol. 2018 Jul 11;9:1598. doi: 10.3389/fimmu.2018.01598. eCollection 2018.

21.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

22.

Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs.

Chondronasiou D, Eisden TTHD, Stam AGM, Matthews QL, Icyuz M, Hooijberg E, Dmitriev I, Curiel DT, de Gruijl TD, van de Ven R.

Vaccines (Basel). 2018 Jul 18;6(3). pii: E42. doi: 10.3390/vaccines6030042.

23.

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

King LA, Lameris R, de Gruijl TD, van der Vliet HJ.

Front Immunol. 2018 Jul 2;9:1519. doi: 10.3389/fimmu.2018.01519. eCollection 2018. Review. Erratum in: Front Immunol. 2018 Nov 20;9:2606.

24.

A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.

Wentink MQ, Verheul HMW, Griffioen AW, Schafer KA, McPherson S, Early RJ, van der Vliet HJ, de Gruijl TD.

Vaccine. 2018 Apr 5;36(15):2025-2032. doi: 10.1016/j.vaccine.2018.02.066. Epub 2018 Mar 5.

25.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

26.

The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.

Schneiders FL, Huijts CM, Reijm M, Bontkes HJ, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Immunobiology. 2018 Feb;223(2):171-177. doi: 10.1016/j.imbio.2017.10.029. Epub 2017 Oct 16.

PMID:
29055564
27.

Immunological effects of everolimus in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ.

Int J Immunopathol Pharmacol. 2017 Dec;30(4):341-352. doi: 10.1177/0394632017734459. Epub 2017 Oct 9.

28.

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.

Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD.

Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.

29.

Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.

van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD.

Cancer Immunol Res. 2017 Nov;5(11):969-977. doi: 10.1158/2326-6066.CIR-17-0110. Epub 2017 Sep 21.

30.

Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.

van Dinther D, Stolk DA, van de Ven R, van Kooyk Y, de Gruijl TD, den Haan JMM.

J Leukoc Biol. 2017 Oct;102(4):1017-1034. doi: 10.1189/jlb.5MR0217-059RR. Epub 2017 Jul 20. Review.

31.

Transcriptional profiling reveals functional dichotomy between human slan+ non-classical monocytes and myeloid dendritic cells.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, Kordasti S, Bontkes HJ, de Gruijl TD, Lindstedt M, van de Loosdrecht AA.

J Leukoc Biol. 2017 Oct;102(4):1055-1068. doi: 10.1189/jlb.3MA0117-037R. Epub 2017 Jul 18.

PMID:
28720687
32.

Comparative phenotypic and functional analysis of migratory dendritic cell subsets from human oral mucosa and skin.

Kosten IJ, van de Ven R, Thon M, Gibbs S, de Gruijl TD.

PLoS One. 2017 Jul 13;12(7):e0180333. doi: 10.1371/journal.pone.0180333. eCollection 2017.

33.

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.

Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J.

Front Immunol. 2017 May 31;8:631. doi: 10.3389/fimmu.2017.00631. eCollection 2017. Review.

34.

High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes.

van de Ven R, Niemeijer AN, Stam AGM, Hashemi SMS, Slockers CG, Daniels JM, Thunnissen E, Smit EF, de Gruijl TD, de Langen AJ.

ERJ Open Res. 2017 May 23;3(2). pii: 00110-2016. doi: 10.1183/23120541.00110-2016. eCollection 2017 Apr.

35.

Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebestyén Z, Kuball J, Bonvin AMJJ, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 May 1;198(9):3759. doi: 10.4049/jimmunol.1700317. No abstract available.

36.

Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function.

Veluchamy JP, Delso-Vallejo M, Kok N, Bohme F, Seggewiss-Bernhardt R, van der Vliet HJ, de Gruijl TD, Huppert V, Spanholtz J.

Sci Rep. 2017 Mar 10;7:43873. doi: 10.1038/srep43873.

37.

In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer.

Veluchamy JP, Lopez-Lastra S, Spanholtz J, Bohme F, Kok N, Heideman DA, Verheul HM, Di Santo JP, de Gruijl TD, van der Vliet HJ.

Front Immunol. 2017 Feb 6;8:87. doi: 10.3389/fimmu.2017.00087. eCollection 2017.

38.

Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression.

Baglio SR, Lagerweij T, Pérez-Lanzón M, Ho XD, Léveillé N, Melo SA, Cleton-Jansen AM, Jordanova ES, Roncuzzi L, Greco M, van Eijndhoven MAJ, Grisendi G, Dominici M, Bonafede R, Lougheed SM, de Gruijl TD, Zini N, Cervo S, Steffan A, Canzonieri V, Martson A, Maasalu K, Köks S, Wurdinger T, Baldini N, Pegtel DM.

Clin Cancer Res. 2017 Jul 15;23(14):3721-3733. doi: 10.1158/1078-0432.CCR-16-2726. Epub 2017 Jan 4. Erratum in: Clin Cancer Res. 2018 Feb 1;24(3):724.

39.

Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases.

Ferns DM, Heeren AM, Samuels S, Bleeker MCG, de Gruijl TD, Kenter GG, Jordanova ES.

J Immunother Cancer. 2016 Nov 15;4:78. doi: 10.1186/s40425-016-0184-3. eCollection 2016.

40.

Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 Jan 1;198(1):308-317. Epub 2016 Nov 28. Erratum in: J Immunol. 2017 May 1;198(9):3759.

41.

MUTZ-3 Langerhans cell maturation and CXCL12 independent migration in reconstructed human gingiva.

Kosten IJ, Spiekstra SW, de Gruijl TD, Gibbs S.

ALTEX. 2016;33(4):423-434. doi: 10.14573/altex.1510301. Epub 2016 May 19.

42.

High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status.

Veluchamy JP, Heeren AM, Spanholtz J, van Eendenburg JD, Heideman DA, Kenter GG, Verheul HM, van der Vliet HJ, Jordanova ES, de Gruijl TD.

Cancer Immunol Immunother. 2017 Jan;66(1):51-61. doi: 10.1007/s00262-016-1919-1. Epub 2016 Oct 25.

43.

Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.

Scheffer HJ, Vroomen LG, de Jong MC, Melenhorst MC, Zonderhuis BM, Daams F, Vogel JA, Besselink MG, van Kuijk C, Witvliet J, de van der Schueren MA, de Gruijl TD, Stam AG, van den Tol PM, van Delft F, Kazemier G, Meijerink MR.

Radiology. 2017 Feb;282(2):585-597. doi: 10.1148/radiol.2016152835. Epub 2016 Sep 6.

PMID:
27604035
44.

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM.

Br J Cancer. 2016 Oct 11;115(8):940-948. doi: 10.1038/bjc.2016.275. Epub 2016 Aug 30.

45.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, Zandvliet ML, Meeuwenoord NJ, Melief CJ, de Gruijl TD, Van der Marel GA, Filippov DV, Ossendorp F, Van der Burg SH.

Oncotarget. 2016 Oct 11;7(41):67087-67100. doi: 10.18632/oncotarget.11512.

46.

Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications.

de Bruin RCG, Lougheed SM, van der Kruk L, Stam AG, Hooijberg E, Roovers RC, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2016 Aug;169:128-138. doi: 10.1016/j.clim.2016.06.012. Epub 2016 Jun 30.

47.

High myeloid-derived suppressor cell frequencies in the duodenum are associated with enteropathy associated T-cell lymphoma and its precursor lesions.

Bontkes HJ, Jordanova ES, Nijeboer P, Neefjes-Borst EA, Cillessen SAGM, Hayat A, Mulder CJ, Bouma G, von Blomberg BM, de Gruijl TD.

Br J Haematol. 2017 Sep;178(6):988-991. doi: 10.1111/bjh.14186. Epub 2016 Jun 24. No abstract available.

PMID:
27341082
48.

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.

Veluchamy JP, Spanholtz J, Tordoir M, Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD, van der Vliet HJ.

PLoS One. 2016 Jun 17;11(6):e0157830. doi: 10.1371/journal.pone.0157830. eCollection 2016.

49.

Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.

Lameris R, de Bruin RC, van Bergen En Henegouwen PM, Verheul HM, Zweegman S, de Gruijl TD, van der Vliet HJ.

Immunology. 2016 Sep;149(1):111-21. doi: 10.1111/imm.12635.

50.

Immune-competent human skin disease models.

Bergers LIJC, Reijnders CMA, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, Gibbs S.

Drug Discov Today. 2016 Sep;21(9):1479-1488. doi: 10.1016/j.drudis.2016.05.008. Epub 2016 Jun 2. Review.

PMID:
27265772

Supplemental Content

Loading ...
Support Center